← AI Companies
Tempus AI operates an AI-powered precision medicine platform that aggregates multimodal clinical and molecular data to enable personalized healthcare and accelerate drug development.
Snapshot
| Country |
USA
|
| Exchange | Nasdaq |
| AI Layer |
app
|
| Sentiment |
52.0% |
| USD Mkt Cap | 10.65B |
| USD Revenue | 1.43B |
| USD Net Income | -254.42M |
| fwd P/E | 14752.50 |
| Price 3M | +21.9% |
| Price 6M | +18.4% |
| Price 1Y | -31.5% |
| Price 2Y | +19.8% |
| USD Share Price | 59.17 |
Price & Size
| Price |
59.01 USD |
| Market Cap |
10.65B USD |
| Shares Outstanding |
175.39M |
| Shares Float |
115.90M |
| 52w Low |
40.77 USD |
| 52w High |
104.32 USD |
| Avg Volume |
6.35M |
Valuation
| P/E (forward) |
14752.5x |
| P/B |
23.88x |
| Enterprise Value |
11.28B USD |
| Book Value / Share |
2.47 USD |
| P/S |
7.44x |
| EV / Revenue |
7.87x |
| EV / EBITDA |
-58.31x |
Income
| Revenue |
1.43B USD |
| Revenue / Share |
8.05 USD |
| EBITDA |
-193.36M USD |
| Net Income |
-254.42M USD |
| EPS (trailing) |
-1.44 USD |
| EPS (forward) |
0.00 USD |
Margins & Profitability
| Gross Margin |
64.0% |
| Operating Margin |
-20.1% |
| Profit Margin |
-17.8% |
| EBITDA Margin |
-13.5% |
| Return on Equity |
-67.4% |
| Return on Assets |
-8.6% |
Cash & Debt
| Total Cash |
815.99M USD |
| Total Debt |
1.44B USD |
| Free Cash Flow |
-93.49M USD |
| Operating Cash Flow |
-237.43M USD |
| Debt / Equity |
3.25x |
| Current Ratio |
3.30x |
| Quick Ratio |
3.01x |
Analyst Consensus
| Target (Mean) |
67.59 USD |
| Target (Median) |
70.00 USD |
| Target (High) |
100.00 USD |
| Target (Low) |
35.00 USD |
| Recommendation |
buy |
| # Analysts |
17 |
Sentiment 52.0%
as of Sep 12, 2026
Positive drivers
Tempus AI continued to expand partnerships with major healthcare providers, leveraging its AI platform for oncology data analytics. Positive analyst coverage highlighted potential revenue growth from new precision medicine contracts in Q3 2026.
Neutral / mixed
The stock showed moderate volatility aligned with broader AI sector movements, with no major earnings surprises reported in the period. Regulatory updates on AI in healthcare remained pending, creating a wait-and-see environment.
Negative drivers
Increased competition from larger tech firms entering the health AI space pressured margins. Some investor concerns arose over delayed product launches and higher-than-expected R&D spending in recent filings.
Bottom line
Overall sentiment for TEM remains slightly positive but tempered by competitive and execution risks, reflecting cautious optimism in the AI healthcare niche.